查看文章

To the Editor: With the peak of coronavirus disease 2019 (COVID-19) expected to occur in many regions of the United States in the coming weeks to months, physicians and patients alike are concerned about the use of immunosuppressive, biologic agents given the increased infection risk. A recent Letter to the Editor highlighted the risk of total infections, upper respiratory tract infections, and nasopharyngitis in patients with psoriasis on immunomodulating biologic therapy. 1

Similar to psoriasis, hidradenitis suppurativa (HS) is an inflammatory skin disease managed effectively with biologic agents when disease burden is high. Adalimumab, a tumor necrosis factor-inhibitor, is currently the only United States Food and Drug Administration (FDA)-approved drug for moderate to severe HS. Compared with patients with psoriasis, patients with HS generally require higher doses of adalimumab, especially during treatment …